Publication: 2584

Publication: 2584

Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Lancet Haematol vol 4 (4) e176-82

Year:: 2017
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 6

Parents:: 2180
Children:: None

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA007968, U10CA033601, U10CA041287, U10CA047559, U10CA077597, U10CA180833, U10CA180836, U10CA180838, U10 CA007968, U10 CA033601, U10 CA180821, U10 CA077597, U10 CA180836, U10 CA041287, U10 CA047559, U10 CA180882, U10 CA180833, U10 CA180838

Corr. Author:
Authors:: Sonali M. Smith Brandelyn N. Pitcher Sin-Ho Jung Nancy L. Bartlett Nina Wagner-Johnston Steven I. Park Kristy L. Richards Amanda F. Cashen Anthony Jaslowski Scott E. Smith Bruce D. Cheson Eric Hsi John P. Leonard

Networks:: CAPITAL, IL017, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-MO011, NC002, NY018, WINCORP

Study
Multiple Studies, or Legacy Studies in Alliance Study:: Alliance-A051201, Alliance-A051202
Phases:: 1

Keywords:: relapsed lymphoma, PI3K, immunomodulatory agents, rituximab, toxicity